ADC Therapeutics SA announced a global workforce reduction of approximately 17 percent to achieve an estimated $10 million in annualized cost savings. The company expects to incur one-time pre-tax charges of approximately $3 million for severance and termination costs, primarily in the second quarter of 2026. ADC Therapeutics SA is a biotechnology company focused on developing and commercializing oncology products.
